樂觀
$100.37
情境價格
$125.160
+1.877 (+1.50%)收盤時
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Mesa Laboratories Inc is currently a hold. The stock's price is at $122.48, which is down 3.94% over the last five days and 19.5% since its last earnings report. While the company has shown a year-to-date increase of 54.20%, the recent drop in share price and an RSI of 30.705 suggest it may be oversold, but caution is warranted due to mixed earnings results and a forward P/E ratio of 34.48, indicating high valuation risks.
Wells Fargo
$94
2026-02-04
Wells Fargo
2026-02-04
目標價
$94
Wells Fargo
$83
2025-12-15
Wells Fargo
2025-12-15
目標價
$83
Jefferies
$115
2025-11-07
Jefferies
2025-11-07
目標價
$115
Wells Fargo
$67
2025-08-07
Wells Fargo
2025-08-07
目標價
$67
Wells Fargo
$100
2025-05-30
Wells Fargo
2025-05-30
目標價
$100
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Mesa Laboratories Reports Q1 2027 Earnings with Mixed Results

Mesa Laboratories to Release Q1 2027 Financial Results on August 10, 2026

Mesa Laboratories Declares Quarterly Dividend of $0.16

Mesa Laboratories Declares Quarterly Dividend

Mesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).
Mesa Laboratories Inc is currently a hold. The stock's price is at $122.48, which is down 3.94% over the last five days and 19.5% since its last earnings report. While the company has shown a year-to-date increase of 54.20%, the recent drop in share price and an RSI of 30.705 suggest it may be oversold, but caution is warranted due to mixed earnings results and a forward P/E ratio of 34.48, indicating high valuation risks.
2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。